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Malaria burden in a birth cohort 
of HIV-exposed uninfected Ugandan infants 
living in a high malaria transmission setting
Abel Kakuru1*, Paul Natureeba1, Mary K. Muhindo1, Tamara D. Clark2, Diane V. Havlir2, Deborah Cohan3, 
Grant Dorsey2, Moses R. Kamya4 and Theodore Ruel5
Abstract 
Background: HIV-exposed, uninfected (HEU) infants suffer high morbidity and mortality in the first year of life com-
pared to HIV-unexposed, uninfected (HUU) infants, but accurate data on the contribution of malaria are limited.
Methods: The incidence of febrile illnesses and malaria were evaluated in a birth cohort of HEU infants. Infants 
were prescribed daily trimethoprim–sulfamethoxazole (TS) prophylaxis from 6 weeks of age until exclusion of HIV-
infection after cessation of breastfeeding. Infants were followed for all illnesses using passive surveillance and routine 
blood smears were done monthly. Malaria was diagnosed as a positive blood smear plus fever. Placental malaria was 
determined by histopathology, placental blood smear and PCR. Risk factors for time to first episode of malaria were 
assessed using a Cox proportional hazards model. Malaria incidence among HEU infants aged 6–12 months was com-
pared to that in other cohorts of HEU and HUU infants from the same region.
Results: Among 361 HEU infants enrolled, 248 completed 12 months of follow-up resulting in 1562 episodes of 
febrile illness and 253 episodes of malaria after 305 person-years of follow-up. The incidence of febrile illness was 
5.12 episodes per person-year (PPY), ranging from 4.13 episodes PPY in the first 4 months of life to 5.71 episodes PPY 
between 5 and 12 months of age. The overall malaria incidence was 0.83 episodes per person-year (PPY), increasing 
from 0.03 episodes PPY in the first 2 months of life to 2.00 episodes PPY between 11 and 12 months of age. There 
were no episodes of complicated malaria. The prevalence of asymptomatic parasitaemia was 1.2 % (19 of 1568 routine 
smears positive). Infants born to mothers with parasites detected from placental blood smears were at higher risk 
of malaria (hazard ratio = 4.51, P < 0.001). HEU infants in this study had a 2.4- to 3.5-fold lower incidence of malaria 
compared to HUU infants in other cohort studies from the same area.
Conclusion: The burden of malaria in this birth cohort of HEU infants living in a high-transmission setting and taking 
daily TS prophylaxis was relatively low. Alternative etiologies of fever should be considered in HEU-infants taking daily 
TS prophylaxis who present with fever.
Trial Registration NCT00993031, registered 8 October, 2009
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Background
As the number of infants born HIV-exposed but unin-
fected (HEU) steadily increases throughout Africa [1], 
it is important to understand their burden of malaria. 
Several early studies suggested that HEU African children 
suffer greater infectious disease morbidity and mortality 
than HIV-unexposed uninfected infants (HUU) [2–7], 
but these studies were performed when women had lim-
ited access to antiretroviral therapy (ART). The World 
Health Organization (WHO) currently recommends that 
all HIV-infected individuals, including pregnant women, 
should take ART, and HEU infants should receive daily 
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trimethoprim-sulfamethoxazole (TS) prophylaxis from 
6 weeks of age until the risk of HIV transmission ends 
and HIV infection is excluded [8]. TS has been shown to 
be effective in reducing the incidence of malaria among 
older children [9–12]. However, accurate data on the 
incidence of malaria among infants of HIV-infected 
mothers receiving ART and who, themselves receive TS, 
are needed to guide clinical management.
The objective of this study was to describe the natu-
ral history of malaria in a birth cohort of Ugandan HEU 
infants who were born to mothers who received ART as 
part of a clinical trial during pregnancy and who them-
selves received TS prophylaxis starting at  ~6 weeks of 
life, as per current WHO guidelines. The incidence of 
malaria and all febrile illnesses and the prevalence of 
asymptomatic parasitaemia at routine visits were meas-
ured over the first year of life. Risk factors for malaria in 
the first year of life were assessed at the time of birth.
Methods
Study design, setting and population
This was a planned secondary data analysis in a birth 
cohort of HEU infants born to HIV-infected mothers 
who were part of a randomized controlled trial of lopi-
navir/ritonavir versus efavirenz-based ART living in 
Tororo district, Uganda [Protease Inhibitors to Reduce 
Malaria Morbidity in HIV-Infected Pregnant Women 
(PROMOTE-PIs), NCT00993031)] [13]. The study site 
is a high malaria transmission setting where transmis-
sion occurs year round with an average entomologi-
cal inoculation rate of 310 infectious bites per person 
per year [14]. For this analysis, all infants who survived 
beyond the first 24  h of life and completed at least one 
visit to the study clinic after discharge from the hospital 
following birth were included. Gestational age was estab-
lished using last menstrual period with confirmation 
by ultrasound [13]. Data from two other cohort studies 
conducted in the same region by the same researchers: 
Interactions Between HIV and Malaria in African Chil-
dren (TCC, NCT00527800) [12] and Chemopreventive 
Therapy for Malaria in Ugandan Children (PROMOTE-
Chemop, NCT00948896) [9], were included to enable 
comparisons with HUU infants and other HEU infants.
Study participant follow‑up
Infants were followed from birth to 1 year of age. At 
birth, placental malaria status was determined from pla-
cental blood and tissue. Infants were seen at monthly 
routine visits and parents were instructed to bring their 
infants to a dedicated study clinic, open 7 days a week, 
for any fever or other illness. All study participants were 
given a long-lasting, insecticide-treated bed net (LLIN) at 
birth and prescribed daily TS prophylaxis from 6 weeks 
of age until they were confirmed to be HIV negative after 
cessation of breastfeeding. At each monthly visit, adher-
ence to TS prophylaxis was assessed by 3-day recall and 
parents were asked if infants were sleeping under an 
LLIN. A thick blood smear for determination of malaria 
parasitaemia by microscopy was performed at every rou-
tine monthly visit.
Malaria diagnosis and treatment
A febrile episode was defined as having a measured tym-
panic temperature of ≥38.0  °C or a history fever in the 
past 24 h. Study participants who presented to the study 
clinic with a febrile episode had a thick blood smear 
done for the detection of malaria parasites. If the blood 
smear was positive, they were diagnosed with malaria 
and a thin blood smear was taken off for identification 
of parasite species. Infants with uncomplicated malaria 
were treated with artemether–lumefantrine (AL) (tab-
lets of 20 mg of artemether and 120 mg of lumefantrine: 
Coartem, Novartis) if they were  ≥4 months old and 
weighing ≥5 kg. Infants with uncomplicated malaria who 
were  <4 months old and weighing  <5  kg were treated 
with quinine.
Laboratory methods
Thick and thin blood smears were stained with 2  % 
Giemsa and examined for malaria parasites by trained 
microscopists. A blood smear was considered negative 
when the examination of 100 high power fields did not 
reveal asexual parasites. All slides were read by a second 
reader, and a third reader settled any discrepancies. Pla-
cental specimens were collected within 30 min of delivery 
in the hospital (or as early as possible, if delivery occurred 
at home). Thick blood smears made from placental blood 
collected from an incision on the maternal surface of pla-
cental tissue, were examined for parasites. Aliquots of 
approximately 25 µL of placental blood were also placed 
on filter paper, air dried and stored for DNA extraction 
and PCR testing for malaria parasites as earlier described 
[15]. Placental tissues were processed for histological evi-
dence of placental malaria as described previously [13]. 
Histological slides were read in duplicate by two trained 
independent readers, and the results were recorded on 
a standardized case-record form; any discrepant results 
were resolved by a third reader. The rate of inter-reader 
agreement was 71.3 % (kappa, 0.48; P < 0.001). The read-
ers were unaware of both the treatment assignment and 
the results of previous reads.
Statistical analysis
Data were double-entered into Access database (Micro-
soft, Redmond, WA, USA) and analysed using Stata 
version 12 (Stata Corp, College Station, TX, USA). 
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Follow-up time started at birth and ended at 1 year of age, 
or the time of premature withdrawal, or when the study 
was stopped prior to reaching 12 months of age because 
of limited funding. An incident episode of malaria was 
defined as having a febrile episode with a positive blood 
smear not preceded by any treatment for malaria in the 
prior 14  days. Comparisons of the incidence of malaria 
between 6 and 12  months of age were made between 
infants enrolled in this study and other cohorts enrolled 
in the same study site using the same methodology. Pla-
cental malaria status was categorized using a categorical 
variable as follows: no parasites or pigment detected by 
any method, only pigment detected by histopathology 
(no parasites), parasites detected by PCR or histopathol-
ogy but not placental blood smear, parasites detected by 
placental blood smear. Time to an infant’s first episode 
of malaria was estimated using Kaplan–Meier survival 
analysis. Associations between risk factors assessed at 
the time of birth and time to first episode of malaria were 
assessed using a Cox proportional hazards model. In all 
analyses, a two-sided P value of <0.05 was considered to 
be statistically significant.
Ethical approval
This study was approved by the Uganda National Coun-
cil of Science and Technology, the Makerere University 
School of Medicine Research Ethics Committee, and the 
University of California, San Francisco Committee for 
Human Research. Informed consent was obtained from 
all mothers at the time of enrolment.
Results
Study profile and subject characteristics
Among 386 HEU infants born to 376 HIV-infected 
women (including ten pairs of twins), 361 infants were 
included in this analysis (Fig. 1). The median gestational 
age at birth was 38.9 weeks (range 29.7–43.0), including 
63 (17.5  %) infants born pre-term (Table  1). Of the 361 
infants included in the analysis, 248 reached 12 months 
of age. The majority of those followed for fewer than 
12 months were due to premature study termination due 
to limited funds (Fig.  1). The median (range) follow-up 
time was 361 (16–365) days. Over the total of 305 per-
son-years of follow-up time, infants were breastfed for 
92 % and received TS for 91 % of the time. Among 361 
children included, 350 were started on TS and 11 were 
withdrawn before TS could be started. Of these 350 chil-
dren, only 31 stopped TS before they reached 1  year of 
age. Of the 31 who stopped TS before 1 year of age, 30 
stopped only 2–63  days before reaching 1  year of age, 
and the remaining child stopped TS 114  days before 
reaching 1 year of age. At routine visits, TS adherence by 
self report was 98 %. Adherence to TS did not change as 
infants aged.
Incidence of malaria and the prevalence of asymptomatic 
parasitaemia
There were 1562 febrile episodes resulting in an over-
all incidence of 5.12 episodes per person year (PPY). 
Malaria was diagnosed in 253 (16.2 %) of the febrile epi-
sodes, resulting in an overall incidence of malaria of 0.83 
malaria episodes PPY. The incidence of malaria steadily 
increased with age over the first year of life, rising from 
0.03 episodes PPY in infants up to 2 months old to 2.00 
episodes PPY in infants between 11 and 12  months old 
(Fig. 2). By contrast the incidence of febrile illnesses over-
all increased over the first 6 months of life and remained 
fairly stable from 6 to 12 months of age. Malaria episodes 
were treated with AL (n  =  243) and quinine (n  =  10). 
There were no episodes of complicated malaria or 
malaria-associated deaths. The incidence of malaria in 
HEU infants 6–12 months old and taking TS prophylaxis 
from this study was comparable to other studies of HEU 
receiving TS, and 2.4- to 3.5-fold lower than for HUU not 
receiving TS in the TCC and PROMOTE-Chemop stud-
ies (Table 2).
Asymptomatic parasitaemia, as determined from thick 
blood smears, was uncommon at routine visits. Among 
1568 thick blood smears performed at monthly routine 
follow-up visits, 19 (1.2 %) were positive for malaria para-
sites among 16 different children; six of them developed 
malaria in the next 30 days, four had malaria during the 
previous 30 days, three had no further blood smears, and 
six became smear negative in the absence of anti-malarial 
therapy.
386 infants born
25 excluded from analyses 
      7 died within 24 hours of delivery 
      6 immediately lost to follow-up 
361 infants included in analyses
113 followed for less than 12 months 
     84 less than 12 months of age when the study ended 
     23 withdrew informed consent 
       6 died 
248 infants completed the 12 month 
follow-up period
Fig. 1 Study profile
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Risk factors for time to first episode of malaria
Overall, 108 children (29.9 %) developed at least one epi-
sode of malaria with a median time to their first episode 
of 225  days (range 42–357  days). Associations between 
risk factors assessed at birth and time to a first episode of 
malaria are presented in Table 3. Only placental malaria 
status was significantly associated with a higher risk of a 
first episode of malaria. Interestingly, compared to infants 
born to mothers with no evidence of placental malaria, 
infants born to mothers with parasites detected by pla-
cental blood smear had a higher risk of malaria in the 
first year of life (adjusted HR = 4.51, 95 % CI 2.10–9.68, 
P < 0.001), but not infants born to mothers with placen-
tal malaria based on the presence of pigment or parasites 
detected only by PCR or histopathology (Table 3; Fig. 3). 
Infants born with low birth weight had a lower risk of 
developing malaria in the first year of life but this did not 
reach statistical significance (adjusted HR = 0.55, 95 % CI 
0.28–1.08, P = 0.08).
Discussion
In this birth cohort of HEU infants living in an area of 
high transmission intensity, the burden of malaria was 
relatively low in the first year of life compared to HUU 
infants from the same area. Asymptomatic parasitaemia 
was rare and all episodes of malaria were uncomplicated, 
with a gradual increase in incidence from 2 to 12 months 
of age. Key characteristics of this birth cohort of HEU 
infants were the provision of LLINs, TS prophylaxis, 
ART for all mothers during pregnancy, and breastfeed-
ing. These data fill an important gap in understanding 
the epidemiology of malaria in this vulnerable and grow-
ing population of HEU in sub-Saharan Africa, who are 
receiving the current standard of care, with TS prophy-
laxis from 6 weeks of life and being born to HIV-infected 
mothers who received ART. The most accurate data prior 
to this report came from the breastfeeding, antiretrovi-
rals and Nutrition (BAN) trial, which reported a 48-week 
incidence of malaria of 0.052 episodes PPY [16]. How-
ever, the BAN trial took place in a clinical context that 
does not represent the current standard of care, because 
the women had not received ART during pregnancy and 
some of the infants (32 %) were born before TS prophy-
laxis had been introduced [16, 17].
As expected, malaria was very rare in HEU infants 
up to two months of age in this cohort. Relative protec-
tion from malaria in the first weeks of life has been well 
described among infants living in endemic areas [18], 
and is assumed to be a result of many factors, including 
Table 1 Characteristics of study participants
a Data are n (%) or median (range) and apply to full cohort unless otherwise 
specified
b Pre-term birth: born at <37 weeks gestation
c Low birth weight: <2.5 kg
d One or more malaria episodes
e Among the 302 who had placental blood smears performed
f Among the 291 who had placental blood polymerase chain reaction (PCR) 
testing for malaria parasites performed
g Among the 312 who had placenta histopathology studies
h Among the 1568 routine smears examined
Characteristic Value (n = 361)a
At birth
Female 167 (46.3 %)
Gestational age, weeks 38.9 (29.7–43.0)
Pre-term birthsb 63 (17.5 %)
Birth weight, kg 2.9 (1.3–4.4)
Low birth weightc 68 (19.4 %)
Maternal HIV treatment arm
Efavirenz 178 (49.3 %)
Lopinavir/ritonavir 183 (50.7 %)
Mother diagnosed with malaria during pregnancyd 29 (8.0 %)
Placental blood
Parasites by smeare 12 (4.0 %)
Parasites by PCRf 25 (18.6 %)
Placental tissue histopathologyg
Parasites and pigment 14 (4.5 %)
Parasites only 7 (2.2 %)
Pigment only 81 (25.9 %)
No parasite or pigment 206 (66.0 %)
During follow-up
Total follow-up time, person-years 305
Incidence of febrile illnesses, episodes per person-
year
5.12
Incidence of malaria, episodes per person-year 0.83
Routine smear showed parasites (n = 1568 blood 
smears)h
19 (1.2 %)
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Age in months
Malari Febrile illness
Episodes of febrile illness 229 247 306 280 268 231 
Episodes of malaria 2 16 40 59 56 80 
Person-years of follow-up 58.5 56.7 52.6 49.9 47.3 40.0 
Fig. 2 Incidence of febrile illnesses and malaria by age category
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transient protection from maternal anti-malarial anti-
bodies that had been transferred in utero [19, 20], fetal 
haemoglobin [21], and riboflavin deficiency [22]. Beyond 
2 months of age, the HEU infants in this cohort likely 
benefitted from the anti-malarial activity of TS, which 
has been well established by other studies [9, 10, 12, 
17, 23]. The incidence of malaria of HEU infants aged 
6–12 months in this cohort was over two to three times 
lower than that of HUU infants in prior studies (TCC 
study and PROMOTE Chemop trial) from the same 
endemic region [9, 10, 12]. While these comparisons are 
vulnerable to bias from the differences in the study time 
periods and populations, the lower incidence of malaria 
Table 2 Malaria burden in children 6–12 months of age living in Tororo, Uganda
* Data from the present study
Study Mother’s HIV 
status
Prescribed TS 
prophylaxis
Date of obser‑
vation
Number of chil‑
dren observed
Episodes 
of malaria
Person years 
of observation
Incidence 
of malaria PPY
TCC 
(NCT00527800)
Negative No Aug 2007–Oct 
2008
99 157 42.8 3.67
Positive Yes Aug 2007–Nov 
2008
200 143 74.8 1.91
PROMOTE-
Chemop 
(NCT00948896)
Negative No Jul 2010–Sep 
2011
98 253 47.9 5.28
Positive Yes Jul 2010–Mar 
2012
197 111 72.4 1.53
PROMOTE PIs* 
(NCT00993031)
Positive Yes Sep 2010–Mar 
2013
302 205 135.3 1.51
Table 3 Risk factors for time to a first episode of malaria
Model includes the 289 participants who had data for these predictors
Variable Categories Number of infants Univariate Mutivariate
HR (95 % CI) P value HR (95 % CI) P value
Gender Male 160 (55.4 %) Reference group Reference group
Female 129 (44.6 %) 1.26 (0.83–1.93) 0.28 1.40 (0.91–2.17) 0.13
Mother’s ART regimen during 
pregnancy
Efavirenz-based 144 (49.8 %) Reference group Reference group
Lopinavir-based 145 (50.2 %) 1.23 (0.81–1.88) 0.33 1.21 (0.79–1.87) 0.38
Pre-term delivery ≥37 weeks 237 (82.0 %) Reference group Reference group
<37 weeks 52 (18.0 %) 1.02 (0.57–1.80) 0.96 1.28 (0.68–2.40) 0.45
Low birth weight ≥2500 g 233 (80.6 %) Reference group Reference group
<2500 g 56 (19.4 %) 0.70 (0.38–1.28) 0.25 0.55 (0.28–1.08) 0.08
Placental malaria status No parasites or pigment 184 (63.7 %) Reference group Reference group
Pigment (not parasites) on histo-
pathology
67 (23.2 %) 1.31 (0.79–2.18) 0.30 1.28 (0.76–2.17) 0.36
Parasites only detected by PCR or 
histopathology
26 (9.0 %) 0.76 (0.33–1.78) 0.53 0.67 (0.29–1.58) 0.36
Parasites detected by placental 
blood smear
12 (4.2 %) 3.98 (1.88–8.42) <0.001 4.51 (2.10–9.68) <0.001
0%
25%
50%
75%
100%
0 30 60 90 120 150 180 210 240 270 300 330 360
Age in days
No parasites or pigment
Pigment only
Parasites only detected by histopathology or PCR
Parasites detected by placental blood smear
Fig. 3 Risk of malaria over the first year of life, by placental malaria 
category
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among HEU in this cohort was likely a result of the pro-
tective efficacy conferred by daily TS prophylaxis. The 
low prevalence of asymptomatic parasitaemia found in 
this study is also consistent with suppression by daily TS 
prophylaxis.
Active placental malaria by blood smear was associ-
ated with an increased risk of malaria over the first year 
of life in this cohort of HEU infants, as has been shown 
in other studies of HUU infants [24–27]. This association 
could simply be confounded by exposure; women with 
placental malaria likely have higher exposure to malaria 
and therefore infants born to them and living in the same 
households will also have a higher exposure to malaria 
[28]. But if that were the sole explanation, one would pre-
dict that infants whose placenta had evidence of infection 
from earlier in pregnancy (suggested by the presence of 
pigment) would also be at increased risk, but this was not 
so in this cohort. It is possible that exposure to malaria 
antigen earlier in pregnancy could confer protection to 
the fetus, counterbalancing the increased risk of expo-
sure. Studies comparing the immune profiles of infants 
born with different in utero and placental exposure to 
malaria may shed light on this theory.
The contrasting pattern of the incidence of malaria 
versus febrile illness over the first year of life has clinical 
implications for the management of HEU infants living 
in malaria-endemic regions. In this cohort, the incidence 
of malaria rose from near zero in the first 2  months of 
life to two episodes PPY among infants between 11 
and 12 months of age, while the incidence of febrile ill-
ness increased only slightly during the first 6  months 
of life and remained steady thereafter. Taken together, 
these patterns underscore the important use of accu-
rate malaria diagnostics to evaluate all fevers in similar 
settings. Clinicians evaluating and treating febrile HEU 
infants, particularly those <2 months old, must not pre-
sume fever to represent malaria and should carefully 
evaluate for non-malarial causes of fever, such as bac-
terial sepsis and viral infections. Conversely, clinicians 
must suspect malaria in older febrile HEU infants, even 
if they are receiving TS. The highest incidence of malaria 
was seen in infants aged 11–12 months despite receiving 
daily TS prophylaxis. This could reflect waning protec-
tion from maternal antibodies or changes in TS adher-
ence. In either case, the higher rates underscore the need 
for additional interventions to reduce malaria incidence 
in similar regions. Infants in this cohort had good clini-
cal outcomes, with no episodes of complicated malaria or 
malaria-associated deaths among 253 episodes of malaria 
treated, but that is most likely a result of prompt diagno-
sis and treatment of malaria in the context of this trial 
and not available in the most limited resource clinical 
settings.
These results add to existing evidence that supports 
the importance of daily TS prophylaxis in preventing 
malaria in HEU children [9, 11, 12]. Recently presented 
data from Botswana have raised the question whether 
TS prophylaxis should be prescribed to all HEU living in 
Africa. The Mpepu study (NCT01229761) randomized 
HEU infants to receive TS or placebo from age 2–4 weeks 
until 15 months; the study was stopped because no mor-
tality benefit was seen in the TS arm; the authors con-
cluded that long term use of TS by HEU infants may not 
be indicated in settings where infants have low risk of 
HIV-transmission and malaria [29]. By contrast, our data 
suggest that in malaria endemic areas, TS can continue to 
play an important role in preventing morbidity and mor-
tality from malaria among HEU infants.
This study had several limitations. The cohort’s sample 
size limited the power to evaluate additional risk factors 
for malaria. Comparisons of malaria incidence among 
infants who were 6–12  months old from other cohort 
studies were vulnerable to confounding by temporal dif-
ferences in malaria transmission which were not adjusted 
for because long term longitudinal data about tempo-
ral changes in malaria transmission in the study area 
were not available. However, it is notable that the other 
cohorts were from the same study site and followed with 
identical malaria diagnostics and study protocols. Finally, 
there was very little follow-up time when infants were 
not taking TS and this limited our ability to separately 
investigate the effect of TS alone on malaria incidence.
Conclusion
In this birth cohort of HEU infants living in a malaria-
endemic region and taking daily TS prophylaxis, the inci-
dence of malaria was relatively low but increased with 
increasing age. However, the burden of febrile illnesses 
was high and remained fairly stable during infancy. Alter-
native etiologies of febrile illnesses other than malaria 
should always be considered in HEU infants taking daily 
TS prophylaxis. While HEU infants living in malaria-
endemic regions benefit from the malaria prophylactic 
efficacy of TS, additional strategies to reduce malaria in 
the important population are needed.
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